NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Europe Microbiome Therapeutics Market Size, Share, Growth and Forecast to 2032

Europe microbiome therapeutics market valued at USD 0.38B in 2023, projected to reach USD 1.54B by 2032 at 16.8% CAGR.

Revenue, 2023

$0.4B

Forecast, 2032

$1.5B

CAGR, 2024-2032

16.8%

Report Coverage

North America

Code: europe-microbiome-therapeutics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The Europe microbiome therapeutics market was valued at USD 0.38 billion in 2023 and is projected to reach USD 1.54 billion by 2032, growing at a CAGR of 16.8%. Rising prevalence of gastrointestinal disorders, increasing regulatory approvals for fecal microbiota transplantation, and surging investment in live biotherapeutic products drive growth. Germany leads the regional market with a 35% share. Key players include Seres Therapeutics, Ferring Pharmaceuticals, and Enterome Bioscience. The market presents significant opportunities in oncology and metabolic applications.

02

Key Highlights

1

Europe microbiome therapeutics market projected to reach USD 1.54B by 2032 at 16.8% CAGR.

2

Germany dominates with 35% regional market share driven by advanced research infrastructure.

3

FMT therapies lead clinical adoption with multiple EU regulatory approvals in 2024-2025.

4

Oncology applications represent the fastest emerging segment at 12% market share.

5

Live biotherapeutic products are the fastest growing product category in the region.

03

Market Overview

Market Context

Europe's microbiome therapeutics landscape is rapidly evolving with strong regulatory frameworks, increasing clinical evidence for FMT and LBP therapies, and growing investment from both public and private stakeholders across Germany, the UK, and France.

Europe's microbiome therapeutics market is in a high-growth phase, driven by rising clinical adoption of FMT therapies and LBPs. Germany, the UK, and France collectively account for 100% of the regional market. Regulatory clarity from EMA is accelerating pipeline development.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Increasing FDA and EMA approvals for FMT-based therapiesGrowing pipeline of live biotherapeutic products targeting oncologyRising consumer awareness of gut-brain axis and neurological applicationsStrategic partnerships between biotech firms and pharma giantsExpansion of microbiome-based diagnostics companion to therapeutics
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 16.8%

Base Year (2023)

$0.4B

Forecast (2032)

$1.5B

CAGR (2024-2032)

16.8%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$0.38B
2024$0.44B
2025$0.52B
2026$0.61B
2027$0.71B
2028$0.83B
2029$0.96B
2030$1.13B
2031$1.32B
2032$1.54B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The market is forecast to grow from USD 0.38B in 2023 to USD 1.54B by 2032 at 16.8% CAGR. Probiotics remain the largest segment while LBPs show the highest growth rate. Germany, UK, and France collectively drive over 100% of regional demand.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America38.0%17.2%United States
Europe30.0%16.8%Germany
Asia Pacific32.0%18.5%China

North America

#1
Share: 38.0%CAGR: 17.2%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 16.8%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of C. difficile infections and IBD across Europe
  • Increasing regulatory approvals for microbiome-based drugs
  • Growing investment in microbiome R&D from venture capital and pharma
06

Market Segmentation

By Type
Market share distribution across 4 segments
By Type — market share by segment, in percent.
SegmentShare
ProbioticsLargest segment driven by consumer adoption and preventive healthcare trends across Western Europe.40.0%
Live Biotherapeutic ProductsFastest growing segment with multiple pipeline candidates in Phase II and III trials.20.0%
Fecal Microbiota TransplantationClinically proven for recurrent C. difficile infections with expanding regulatory approvals in Europe.18.0%
PrebioticsGrowing demand from food and supplement industries targeting gut health improvement.22.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 5 segments
By Application — market share by segment, in percent.
SegmentShare
Gastrointestinal DisordersDominant segment driven by C. difficile infections, IBD, and IBS prevalence in Europe.45.0%
Infectious DiseasesApplications in antibiotic-resistant infections and immune modulation therapies.20.0%
Metabolic DisordersEmerging applications in obesity, diabetes, and metabolic syndrome management.15.0%
OncologyMicrobiome modulation to enhance immunotherapy response in solid tumors.12.0%
Neurological DisordersEarly-stage research on gut-brain axis for depression, autism, and Parkinson's.8.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Pharmaceutical Companies
07

Regional Analysis

1

North America

Lead: United States
CAGR: 17.2%Share: 38.0%

Largest market globally driven by FDA approvals and strong venture capital funding for microbiome startups.

2

Europe

Lead: Germany
CAGR: 16.8%Share: 30.0%

Second-largest market with strong research infrastructure and growing EMA regulatory approvals.

3

Asia Pacific

Lead: China
CAGR: 18.5%Share: 32.0%

Fastest growing region due to large patient population and increasing healthcare expenditure.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
Germany
35.0%
+17.5%
United Kingdom
33.0%
+16.2%
France
32.0%
+15.8%
08

Competitive Landscape

S

Seres Therapeutics

United States

Leader150M

Pioneer in live biotherapeutic products with FDA-approved Vowst for recurrent CDI and robust oncology pipeline.

Cambridge-based microbiome therapeutics pioneer leading LBP development with FDA-approved oral FMT product Vowst.

F

Ferring Pharmaceuticals

Switzerland

Challenger2.1B

Swiss-based pharma with Rebyota, the first FDA-approved rectal FMT therapy, expanding into immunocompromised patient populations.

Swiss pharmaceutical company specializing in reproductive health and biologics with the first FDA-approved rectal FMT therapy Rebyota.

E

Enterome Bioscience

France

Follower85M

French biotech focused on gut microbiome-derived biomarkers and therapeutics for oncology and inflammatory diseases.

French biotech leveraging metagenomics to develop microbiome-derived diagnostics and therapeutics for oncology and inflammation.

09

Recent Developments

25
2025Seres Therapeutics

Initiated Phase II clinical trial of SER-262 in combination with pembrolizumab for solid tumors.

24
2024Ferring Pharmaceuticals

Received expanded FDA approval for Rebyota in immunocompromised patients with recurrent C. difficile infection.

10

Regulatory Landscape

EMA Advanced Therapy Medicinal Products (ATMP) classification framework governs live biotherapeutic product approvals in EuropeEU Novel Food Regulation (2015/2283) regulates probiotic and prebiotic products requiring safety assessments before market entry
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

High-growth opportunity in LBPs and oncology applications with 16.8% CAGR through 2032.

Operators

Expand manufacturing capabilities and pursue EMA ATMP designation to capture growing pipeline demand.

Policymakers

Standardize microbiome profiling protocols to accelerate clinical trial timelines across EU member states.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.